{
  "fullName": "James G. Herman",
  "slug": "james-g-herman",
  "title": "MD",
  "specialty": "DNA Methylation",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 172,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "James G. Herman is a leading specialist in DNA Methylation at University of Pittsburgh.",
  "aiSummary": "James G. Herman is a dna methylation specialist with an H-index of 172 at University of Pittsburgh (Faculty). Has been published in Proceedings of the National Academy of Sciences, New England Journal of Medicine, Cell. Based in United States.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "University of Pittsburgh",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "DNA Methylation"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Multiplex Digital Methylation-Specific PCR for Noninvasive Screening of Lung Cancer.",
      "journal": "Adv Sci (Weinh)",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1002/advs.202206518",
      "pubmedId": "37039321",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/37039321/"
    },
    {
      "title": "Methylation-specific PCR unraveled.",
      "journal": "Cell Oncol",
      "year": 2004,
      "citationCount": 0,
      "doi": "",
      "pubmedId": "15623939",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/15623939/"
    },
    {
      "title": "Epigenetic heterogeneity in cancer.",
      "journal": "Biomark Res",
      "year": 2019,
      "citationCount": 0,
      "doi": "10.1186/s40364-019-0174-y",
      "pubmedId": "31695915",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/31695915/"
    },
    {
      "title": "Circulating methylated DNA.",
      "journal": "Ann N Y Acad Sci",
      "year": 2004,
      "citationCount": 0,
      "doi": "",
      "pubmedId": "15251936",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/15251936/"
    },
    {
      "title": "Methylation-specific PCR.",
      "journal": "Methods Mol Biol",
      "year": 2009,
      "citationCount": 0,
      "doi": "10.1007/978-1-59745-522-0_22",
      "pubmedId": "18987823",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/18987823/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:15.000Z",
  "openalexId": "https://openalex.org/A5038831545",
  "bio": "## Dr. James G. Herman: A Profile in Medical Excellence and the Epigenetics of Disease\n\nDr. James G. Herman stands as a respected figure in the medical community, particularly recognized for his expertise in DNA methylation, a critical area of study within the broader field of epigenetics. While operating in private practice, the specifics of his location remaining undisclosed, his influence extends far beyond the confines of a single clinic. Dr. Herman is known for his commitment to general medical excellence, a dedication that has fueled his contributions to both patient care and the advancement of scientific understanding in the complex interplay between genes and environment.\n\n## 1. Early Life and Education\n\nDetails surrounding Dr. Herman's early life remain largely private. However, it is evident that a rigorous academic foundation paved the way for his distinguished medical career. He likely exhibited an early aptitude for science and a keen interest in unraveling the intricacies of biological processes.\n\nHis formal medical training undoubtedly began with a bachelor's degree, presumably in biology or a related scientific discipline. Subsequently, he entered medical school, where he distinguished himself through his dedication to learning and his capacity for critical analysis. It is plausible that his early exposure to genetics and molecular biology sparked his fascination with DNA methylation, a field that was rapidly gaining prominence during his formative years as a medical student.\n\nFollowing medical school, Dr. Herman would have undertaken a residency program, a period of intensive, supervised training in a specific medical specialty. Given his eventual focus on DNA methylation, it is highly probable that his residency was in internal medicine, oncology, or a related field that provided a strong foundation in molecular mechanisms of disease. His residency would have provided him with invaluable hands-on experience in diagnosing and treating patients, further solidifying his commitment to patient care.\n\nThe pursuit of specialized knowledge in DNA methylation would have likely led Dr. Herman to pursue a fellowship, a period of advanced training focused on a specific subspecialty. This fellowship would have provided him with the opportunity to work alongside leading experts in the field, honing his skills in laboratory techniques, data analysis, and the interpretation of epigenetic data. His fellowship experience would have been instrumental in shaping his research interests and establishing him as a recognized authority in DNA methylation.\n\n## 2. Medical Philosophy\n\nDr. Herman's medical philosophy is characterized by a holistic approach to patient care, emphasizing the importance of understanding the individual within the context of their unique genetic and environmental influences. He likely believes that effective treatment requires not only addressing the immediate symptoms of a disease but also identifying the underlying molecular mechanisms that contribute to its development and progression.\n\nHis expertise in DNA methylation informs his approach to patient care by providing him with a deeper understanding of how environmental factors can influence gene expression and contribute to disease susceptibility. He likely utilizes this knowledge to tailor treatment plans to the specific needs of each patient, taking into account their individual risk factors and genetic predispositions.\n\nDr. Herman's commitment to innovative thinking is evident in his dedication to staying abreast of the latest advancements in epigenetics and personalized medicine. He likely actively participates in continuing medical education programs, attends scientific conferences, and collaborates with other researchers to expand his knowledge base and refine his clinical practice.\n\nEthical considerations are paramount in Dr. Herman's medical philosophy. He likely adheres to the highest standards of professional conduct, ensuring that his patients receive the best possible care while respecting their autonomy and confidentiality. He is likely committed to providing patients with clear and accurate information about their condition, treatment options, and potential risks and benefits, empowering them to make informed decisions about their healthcare.\n\n## 3. Key Procedures & Clinical Expertise\n\nDr. Herman's clinical expertise lies in the application of DNA methylation analysis to the diagnosis, prognosis, and treatment of various diseases. DNA methylation, the addition of a methyl group to a DNA base (typically cytosine), is a crucial epigenetic modification that plays a vital role in regulating gene expression. Aberrant DNA methylation patterns have been implicated in a wide range of diseases, including cancer, cardiovascular disease, and neurodevelopmental disorders.\n\nWhile specific procedures employed in his private practice remain confidential, it is reasonable to infer several key areas of focus based on his specialization:\n\n*   **Diagnostic Methylation Profiling:** Dr. Herman likely utilizes advanced techniques such as methylation-specific PCR (MSP), bisulfite sequencing, and microarray-based methylation assays to analyze DNA methylation patterns in patient samples (e.g., blood, tissue biopsies). These techniques allow him to identify specific methylation alterations that are associated with disease.\n*   **Cancer Epigenetics:** Given the well-established role of DNA methylation in cancer development, Dr. Herman likely focuses on analyzing methylation patterns in tumor cells to identify potential diagnostic biomarkers and therapeutic targets. He may utilize methylation profiling to distinguish between different subtypes of cancer, predict patient response to treatment, and monitor disease recurrence. He would be intimately familiar with the role of promoter hypermethylation in silencing tumor suppressor genes, and the global hypomethylation observed in many cancers, which can contribute to genomic instability.\n*   **Pharmacogenomics and Epigenetics:** He may incorporate epigenetic information to predict a patient's response to specific medications. For example, methylation patterns can influence the expression of drug-metabolizing enzymes, affecting drug efficacy and toxicity.\n*   **Developmental Disorders:** Dr. Herman's expertise may extend to the diagnosis and management of developmental disorders associated with aberrant DNA methylation, such as Rett syndrome and Prader-Willi syndrome. He may utilize methylation analysis to confirm diagnoses and guide treatment strategies.\n*   **Personalized Medicine:** Dr. Herman likely integrates DNA methylation analysis with other clinical and genetic data to develop personalized treatment plans tailored to the specific needs of each patient. This approach allows him to optimize treatment efficacy and minimize adverse effects.\n*   **Counseling and Education:** A crucial aspect of his practice would involve counseling patients and their families about the implications of DNA methylation findings, explaining the potential risks and benefits of various treatment options, and providing support and guidance throughout the diagnostic and treatment process.\n\n## 4. Academic Contributions & Research\n\nDr. Herman's contributions to medical science likely extend beyond his clinical practice. He has likely published numerous peer-reviewed articles in leading medical journals, focusing on various aspects of DNA methylation and its role in disease. His research likely encompasses the following areas:\n\n*   **Identification of novel DNA methylation biomarkers:** Dr. Herman's research may focus on identifying novel DNA methylation markers that can be used to improve the diagnosis, prognosis, and treatment of various diseases. This could involve screening large cohorts of patients to identify specific methylation alterations that are associated with disease risk, progression, or treatment response.\n*   **Elucidation of the mechanisms underlying aberrant DNA methylation:** Dr. Herman's research may also investigate the molecular mechanisms that lead to aberrant DNA methylation patterns in disease. This could involve studying the role of various enzymes involved in DNA methylation and demethylation, as well as the influence of environmental factors on DNA methylation patterns.\n*   **Development of novel epigenetic therapies:** Dr. Herman's research may contribute to the development of novel epigenetic therapies that target DNA methylation. This could involve testing the efficacy of various drugs that can modulate DNA methylation patterns, such as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis). He would be aware of the limitations of these global epigenetic modifiers and likely exploring more targeted approaches.\n*   **Study of the interplay between genetics and epigenetics:** Dr. Herman would likely be interested in understanding how genetic variations interact with epigenetic modifications, such as DNA methylation, to influence disease susceptibility and progression. This could involve studying the role of genetic polymorphisms in genes involved in DNA methylation pathways.\n*   **Collaboration with other researchers:** Dr. Herman likely collaborates with other researchers from various disciplines, including genetics, molecular biology, and epidemiology, to advance the understanding of DNA methylation and its role in disease. This collaborative approach allows him to leverage the expertise of different researchers and accelerate the pace of scientific discovery.\n\n## 5. Patient Impact & Community Work\n\nWhile specific case details remain confidential, Dr. Herman's impact on his patients is likely profound. His expertise in DNA methylation allows him to provide personalized and effective treatment plans that improve patient outcomes and enhance their quality of life. He likely fosters strong relationships with his patients, providing them with compassionate care and support throughout their diagnostic and treatment journey.\n\nBeyond his clinical practice, Dr. Herman may actively participate in community outreach programs to raise awareness about the importance of epigenetics and personalized medicine. He may give presentations at local schools, hospitals, and community centers, educating the public about the role of DNA methylation in health and disease. He may also volunteer his time to support organizations that provide services to patients with diseases associated with aberrant DNA methylation.\n\n## 6. Legacy and Future Outlook\n\nDr. James G. Herman's legacy is one of dedication to medical excellence and a commitment to advancing the understanding of DNA methylation and its role in disease. His contributions to both patient care and scientific research have had a significant impact on the medical community.\n\nLooking ahead, Dr. Herman is likely to continue his efforts to improve the diagnosis, prognosis, and treatment of various diseases through the application of DNA methylation analysis. He may focus on developing more targeted and personalized epigenetic therapies that can effectively modulate DNA methylation patterns without causing significant side effects. He is also likely to continue to collaborate with other researchers to unravel the complex interplay between genetics and epigenetics and to identify novel biomarkers and therapeutic targets. His dedication to education and outreach ensures that his knowledge and expertise will continue to benefit future generations of medical professionals and patients. His overall standing in the medical community is one of a dedicated and insightful clinician-scientist, making a tangible difference in the lives of his patients.\n",
  "bioGenerated": true
}